RecruitingEarly Phase 1NCT06414681
Combination of Tagraxofusp with Pacritinib in Patients with Intermediate-1 or Higher Myelofibrosis, Who Have Had Prior Therapy with the Approved JAK Inhibitors or in Which Therapy with the Approved JAK Inhibitors is Not Appropriate, Contraindicated or Declined
Studying Primary myelofibrosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Kansas Medical Center
- Principal Investigator
- Abdulraheem Yacoub, Doctor of MedicineUniversity of Kansas Medical Center
- Intervention
- Tagraxofusp(drug)
- Enrollment
- 20 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2026
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06414681 on ClinicalTrials.govOther trials for Primary myelofibrosis
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07590986Identification of MPN-specific Antigens and Anti-MPN TCRs in Myeloproliferative NeoplasmUniversité Catholique de Louvain
- RECRUITINGPHASE1NCT07480824To Evaluate the Pharmacokinetics and Safety of TQ05105 Tablet in Hepatic Impairment SubjectsChia Tai Tianqing Pharmaceutical Group Co., Ltd.
- RECRUITINGPHASE2NCT07394153Pacritinib For Bone Marrow Fibrosis In Patients With Myelofibrosis Who Have ThrombocytopeniaGrupo Español de Enfermedades Mieloproliferativas Crónicas PH Negativas
- RECRUITINGPHASE1NCT07104799Momelotinib During and After HCT in MyelofibrosisMassachusetts General Hospital
- RECRUITINGPHASE3NCT07317700A Clinical Trial of Flonoltinib Maleate for Intermediate or High-Risk MyelofibrosisChengdu Zenitar Biomedical Technology Co., Ltd
- RECRUITINGPHASE1, PHASE2NCT07128381Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)M.D. Anderson Cancer Center
- RECRUITINGPHASE1, PHASE2NCT06887803A Study of Roginolisib in Combination With Ruxolitinib in Patients With Myelofibrosis (MF) Who Are Unresponsive to JAK InhibitorsiOnctura
- RECRUITINGPHASE1, PHASE2NCT07281781Treating Anemia in Myelofibrosis With Repurposed Drugs (Nelfinavir) That Restore Iron Delivery to the Bone MarrowUniversity of California, Irvine